RT @JohnEbbenMDPhD
10.5% is a very substantial number, esp considering how actionable many mutations are in #NSCLC! I know we have a long way to go in providing appropriate #NGS to all pts, but seems like we should also be including pts with #squamouscell #LCSM https://twitter.com/DAielloMD/status/1633275192116953091

10.5% is a very substantial number, esp considering how actionable many mutations are in #NSCLC! I know we have a long way to go in providing appropriate #NGS to all pts, but seems like we should also be including pts with #squamouscell #LCSM
---
RT @DAielloMD
3/26 #TumorBoardTuesday #LCSM
👨🏻‍🏫Mini tweetorial 1👩🏻‍🏫

⭐️~10.5% of pts w SCC have actionable alterations
🕵🏻‍♀️Consider NGS in nonadeno #NSCLC pts who
1⃣🚭or light 🚬hx (1-10 pack y…
https://twitter.com/DAielloMD/status/1633275192116953091

10.5% is a very substantial number, esp considering how actionable many mutations are in #NSCLC! I know we have a long way to go in providing appropriate #NGS to all pts, but seems like we should also be including pts with #squamouscell #LCSM
---
RT @DAielloMD
3/26 #TumorBoardTuesday #LCSM
👨🏻‍🏫Mini tweetorial 1 👩🏻‍🏫

⭐️~10.5% of pts w SCC have actionable alterations
🕵🏻‍♀️Consider NGS in nonadeno NSCLC pts w
1⃣ 🚭or light 🚬hx (1-10 pack yr…
https://twitter.com/DAielloMD/status/1633272850655182848

RT @JohnEbbenMDPhD
A huge thank you to @ShrutiPatelMD -- the Queen of the #lcsm meme & the legendary @NarjustFlorezMD for taking us through the ins and outs of 1L IO in #Squamouscell #lungcancer, just in time for #TTLC23! Take a look at this summary of the conversation. @NSethakorn https://twitter.com/JohnEbbenMDPhD/status/1628961063550038016

RT @JohnEbbenMDPhD
A huge thank you to @ShrutiPatelMD -- the Queen of the #lcsm meme & the legendary @NarjustFlorezMD for taking us through the ins and outs of 1L IO in #Squamouscell #lungcancer, just in time for #TTLC23! Take a look at this summary of the conversation. @NSethakorn https://twitter.com/JohnEbbenMDPhD/status/1628961063550038016

RT @JohnEbbenMDPhD
@TumorBoardTues @ShrutiPatelMD @NarjustFlorezMD @LungAssociation @DrSteveMartin @FawziAbuRous @esinghimd @RenoHemonc @HemOncFellows 4/5 #TumorBoardTuesday
Thurs Case🎀

📷TBT in an image:

Check out this algo to help select IO vs chemoIO strat in #squamouscell #lcsm lung cancer 1L setting.
No head-to-head 👊data to define clear winner, but pembro, cemiplimab, and ipi/nivo approved based on OS benefit.

A huge thank you to @ShrutiPatelMD -- the Queen of the #lcsm meme & the legendary @NarjustFlorezMD for taking us through the ins and outs of 1L IO in #Squamouscell #lungcancer, just in time for #TTLC23! Take a look at this summary of the conversation. @NSethakorn
---
RT @JohnEbbenMDPhD
@TumorBoardTues @ShrutiPatelMD @NarjustFlorezMD @LungAssociation @DrSteveMartin @FawziAbuRous @esinghimd @RenoHemonc @HemOncFellows 3/5 #TumorBoardTu…
https://twitter.com/JohnEbbenMDPhD/status/1628961063550038016

RT @JohnEbbenMDPhD
@TumorBoardTues @ShrutiPatelMD @NarjustFlorezMD @LungAssociation @DrSteveMartin @FawziAbuRous @esinghimd @RenoHemonc @HemOncFellows 4/5 #TumorBoardTuesday
Thurs Case🎀

📷TBT in an image:

Check out this algo to help select IO vs chemoIO strat in #squamouscell #lcsm lung cancer 1L setting.
No head-to-head 👊data to define clear winner, but pembro, cemiplimab, and ipi/nivo approved based on OS benefit.